Eisbach
Developer of novel medicines designed to target chromatin regulatory mechanisms. The company focuses on molecular vulnerabilities arising in cancer genomes by leveraging epigenetic mechanisms to stop ...
Valuation
$0
Share Price
N/A
Total Raised
$12.5M
Last Round
N/A